Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid

Journal of the National Cancer Institute

Volumn 88, Issue 2, 1996, Pages 123-125

  Anzano, Mario A ^a,d   Peer, Christopher W ^a   Smith, Joseph M ^a   Mullen, Larry T ^a   Shrader, Mark W ^b   Logsdon, Daniel L ^b   Driver, Craig L ^b   Brown, Charles C ^a   Roberts, Anita B ^a   Sporn, Michael B ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; RALOXIFENE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; FEMALE; HORMONE INHIBITION; MOUSE; NONHUMAN;

EID: 13344259303     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.2.123     Document Type: Article

References (21)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995 [published erratum appears in CA Cancer J Clin 1995;45:127-8]. CA Cancer J Clin 1995;45:8-30.
2. Jordan VC. The development of tamoxifen for breast cancer therapy. In: Jordan VC, editor. Long-term tamoxifen treatment for breast cancer. Madison: Univ Wisconsin Press, 1994:3-26.
3. Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB, et al. Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990;26:680-4.
4. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83:1450-9.
5. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group [see comment citations in Medline]. Lancet 1992;339:1-15, 71-85.
6. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN, Use of tamoxifen for breast cancer: twenty-eight years later [see comment citation in Medline]. J Clin Oncol 1995; 13:513-29.
7. Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1995;1:467-72.
8. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4.
9. Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 1991;83:492-6.
10. Man XL, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 1992;52:1360-3.
11. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993;53: 3919-24.
12. Anzano MA, Smith JM, Uskokovic MR, Peer CW, Mullen LT, Letterio JJ, et al. lα,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994;54:1653-6.
13. Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 1994;54:4614-7.
14. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983;32:1031-6.
15. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, et al. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]- phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 1984;27:1057-66.
16. Black LJ, Salo M, Rowley ER, Magee DE, Bekele A, Williams DC, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9.
17. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ, et al. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990; 62:244-78.
18. Kempthorne O, Folks L, Probability, statistics, and data analysis. Ames: Iowa State Univ Press, 1971:284-6.
19. Mantel N. Chi-square tests with one degree of freedom: extension of the Mantel-Haenszel procedure. J Am Slat Assoc 1963; 58:690-700.
20. Evans G, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994;134:2283-8.
21. Sporn MB. Combination chemoprevention of cancer. Nature 1980;287:107-8.